Provider intervention associated with usage decline of high risk meds

Intervention designed to impact use of high-risk medications evaluated as part of CMS Star metric

Prime sent letters to doctors to let them know they had prescribed high-risk medications to Medicare members. The intervention group’s high-risk medication percentage declined more than the control group. It was a statistically significant difference. Certain medications carry a greater risk of adverse events for the older adults than for younger people. Safer options exist for many high-risk medications.

Impact of First Fill Intervention on High-risk Medication Usage in a One Million Member Medicare Population (Fall 2016)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

August 28, 2024

Clinical News: August 2024

Your monthly source for drug information highlights

Perspectives

August 28, 2024

Drug Approvals Monthly Update: August 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

Perspectives

August 27, 2024

Expert Clinical Network Insights: August 2024

A look into our Expert Clinical Network (ECN) — part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance

View all news